Mazor Robotics Introduces Mazor X For Robotic Spine Surgery

Mazor Robotics Ltd. (NASDAQ:MZOR) , an Israel-based developer of robotic technology and products, recently introduced Mazor X, a revolutionary platform for spine surgeries using highly automated robotic technologies.

The company is slated to commercially launch the FDA-cleared Mazor X by Oct 2016. Meanwhile, Mazor Robotics recently agreed to a commercial co-promotion and co-development deal with Medtronic (NYSE:MDT) , under which the latter has already added 15 Mazor X systems to its cart.

Mazor X is an assurance platform in the market of spinal surgeries that provides a unified solution to all the tribulations associated to spinal surgery. The uniqueness of the product is concealed in its functioning technique, as it utilizes multidisciplinary principles of analytical tools, multiple data-source, precision guidance, optical tracking, intra-operative verification and connectivity technologies to address the target market.

Mazor X collaborates three major processes, namely, Pre-operative analytics, Intra operative Guidance and Realtime 3D Verification to generate accurate results. Notably, the X-Align module of the Pre-operative analytics process creates a holistic alignment plan for patients by combining biomechanical logic and virtual surgical tools (computerized calculations).

Mazor Robotics has been keen on transforming spine surgery from freehand procedures to highly efficient robotic technologies for long. Notably, the Renaissance Guidance system of the company is a similar product that provides spinal surgical solutions using high-end technologies. As per a report by StarTribune, more than 16,000 successful spinal surgeries have been done worldwide with the Renaissance system.

We believe that the introduction of this new system will expand Mazor Robotics’ portfolio of robot-based spinal surgery products. In fact, the recently formed partnership with Medtronic is going to enhance Mazor Robotics’ market reach and propel growth over the long haul. Notably, the company has received 11 Renaissance system orders in the second quarter of 2016.

The Mazor X is likely to be a path breaker, as it is the result of all the attempts by the company over the past several years to proactively reach target customers in the market of robot-based spinal surgeries. We believe that this will drive the company’s top-line growth in the long haul.

Zacks Rank & Key Picks

Currently, Mazor Robotics has a Zacks Rank #4 (Sell).

Better-ranked stocks in the medical instrument sector include ABIOMED Inc. (NASDAQ:ABMD) , Masimo Corporation (NASDAQ:MASI) and Medtronic plc. (MDT). Notably, ABIOMED and Masimo Corporation sport a Zacks Rank #1 (Strong Buy).